| Literature DB >> 29764496 |
Yu Qing Huang1, Katsiaryna Traore1, Badr Ibrahim2, Maida J Sewitch1,3,4, Lily H P Nguyen5,6,7.
Abstract
BACKGROUND: Randomized controlled trials are the gold standard in medical and surgical research to assess the efficacy of therapeutic interventions. The reporting of these trials should be of high quality to allow readers' appropriate interpretation and application.Entities:
Keywords: CONSORT adherence; RCTs in otolaryngology; Reporting quality
Mesh:
Year: 2018 PMID: 29764496 PMCID: PMC5952888 DOI: 10.1186/s40463-018-0277-8
Source DB: PubMed Journal: J Otolaryngol Head Neck Surg ISSN: 1916-0208
Fig. 1Flow Diagram of Article Selections
Selected Journals in ORL-HNS
| Journal Name | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
a Journals endorsing CONSORT http://www.consort-statement.org/about-consort/endorsers
Frequency and Percentage of Adherence to Individual Criterion of the CONSORT 2010 Checklist
| Criterion | CONSORT item | Frequency | % |
|---|---|---|---|
| 1a | Identification as a randomized trial in the title | 80 | 44.0% |
| 1b | Structured summary of trial design, methods, results, and conclusions | 5 | 2.7% |
| 2a | Scientific background and explanation of rationale | 182 | 100% |
| 2b | Specific objectives or hypotheses | 182 | 100% |
| 3a | Description of trial design (such as parallel, factorial) including allocation ratio | 182 | 100% |
| 3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | 3 | 100% |
| 4a | Eligibility criteria for participants | 168 | 92.3% |
| 4b | Settings and locations where the data were collected | 140 | 76.9 |
| 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | 181 | 99.5% |
| 6a | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed | 77 | 42.3% |
| 6b | Any changes to trial outcomes after the trial commenced, with reasons | 1 | 100% |
| 7a | How sample size was determined | 74 | 40.6% |
| 7b | When applicable, explanation of any interim analyses and stopping guidelines | 2 | 100% |
| 8a | Method used to generate the random allocation sequence | 106 | 58.6% |
| 8b | Type of randomization; details of any restriction (such as blocking and block size) | 45 | 24.7% |
| 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | 113 | 62.1% |
| 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | 12 | 6.6% |
| 11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how | 108 | 59.7% |
| 11b | If relevant, description of the similarity of interventions | 54 | 32.3% |
| 12a | Statistical methods used to compare groups for primary and secondary outcomes | 176 | 96.7% |
| 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses | 23 | 88.5% |
| 13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome | 171 | 94.0% |
| 13b | For each group, losses and exclusions after randomization, together with reasons | 146 | 80.2% |
| 14a | Dates defining the periods of recruitment and follow-up | 96 | 52.7% |
| 14b | Why the trial ended or was stopped | 1 | 100% |
| 15 | A table showing baseline demographic and clinical characteristics for each group | 132 | 72.5% |
| 16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | 164 | 90.1% |
| 17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) | 59 | 32.4% |
| 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended | 13 | 41.9% |
| 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | 7 | 6.5% |
| 19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) | 138 | 78.0% |
| 20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | 109 | 59.9% |
| 21 | Generalizability (external validity, applicability) of the trial findings | 59 | 32.4% |
| 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | 175 | 96.2% |
| 23 | Registration number and name of trial registry | 19 | 10.4% |
| 24 | Where the full trial protocol can be accessed, if available | 7 | 3.8% |
| 25 | Sources of funding and other support (such as supply of drugs), role of funders | 156 | 85.7% |
Adapted from www.consort-statement.org